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Liposome-encapsulation has been suggested as method to improve the efficacy of
ciprofloxacin against the intracellular pathogen, Francisella tularensis. Early work with
a prototype formulation, evaluated for use against the F. tularensis live vaccine strain,
showed that a single dose of liposomal ciprofloxacin given by the intranasal or
inhalational route could provide protection in a mouse model of pneumonic tularemia.
Liposomal ciprofloxacin offered better protection than ciprofloxacin given by the same
routes. Liposomal ciprofloxacin has been further developed by Aradigm Corporation
for Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic
fibrosis bronchiectasis. This advanced development formulation is safe, effective and
well tolerated in human clinical trials. Further evaluation of the advanced liposomal
ciprofloxacin formulation against the highly virulent F. tularensis Schu S4 strain has shown
that aerosolized CFI (Ciprofloxacin encapsulated in liposomes for inhalation) provides
significantly better protection than oral ciprofloxacin. Thus, liposomal ciprofloxacin is a
promising treatment for tularemia and further research with the aim of enabling licensure
under the animal rule is warranted.
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INTRODUCTION
The extremely low infectious dose and severe disease follow-
ing inhalation previously led to the development of Francisella
tularensis as a biological weapon by Russia, Japan, and the USA
(Dennis et al., 2001). To combat the threat of a deliberate release,
there is a need for an easily administered therapy which can be
used in the event of a mass casualty situation. The latest con-
sensus statement on tularemia as a biological weapon suggested
ciprofloxacin or doxycycline should be given in the event of amass
casualty situation (Dennis et al., 2001).
Ciprofloxacin, a broad spectrum second generation fluo-
roquinolone, has been used to treat infections for over 20
years. Tularemia outbreaks in Spain (Perez-Castrillon et al.,
2001) and Turkey (Meric et al., 2008) have been successfully
treated with ciprofloxacin. However, the outbreaks in Spain and
Turkey were likely caused by the less virulent type B form of
Francisella tularensis (Hepburn and Simpson, 2008). The effi-
cacy of ciprofloxacin against the more virulent type A strains
in humans is less well understood. Animal models of infection
with the type A strain Schu S4 suggest that orally delivered
ciprofloxacin is only effective against type A systemic infections
if administered within 24 h of challenge (Piercy et al., 2005).
Furthermore, studies using an animal model of pneumonic infec-
tion with a type A strain, the most fatal form of the disease,
suggest that orally delivered ciprofloxacin offers poor protection
(Steward et al., 2006).
Enhancing cellular delivery of antibiotics by encapsulation in
liposomes has been suggested as a method to improve antibiotic
efficacy against intracellular pathogens (Pinto-Alphandary et al.,
2000).Macrophages which are infected by F. tularensis can take up
liposomes containing antibiotics, enabling intracellular delivery
and a close proximity between the drug and bacteria. In addi-
tion, the inhalation of encapsulated drugs, such as ciprofloxacin,
enables high sustained concentrations of drugs to be achieved in
the lungs. For the pneumonic form of tularemia, this approach
has an obvious advantage and, if administered soon after infec-
tion, encapsulated antibiotics could reduce or prevent the spread
of disease and reduce mortality. Without encapsulation, small
drugs such as ciprofloxacin are rapidly cleared after administra-
tion into the lung (Wong et al., 1995, 2003). This review describes
early studies evaluating the efficacy of a prototype liposomal
ciprofloxacin against F. tularensis and further development of the
novel antibiotic preparation.
PRELIMINARY STUDIES
An initial liposomal ciprofloxacin preparation comprised neg-
atively charged liposomes prepared from phosphatidylcholine:
cholesterol: phosphatidyl serine (in a ratio of 7:3:1) with 45%
of the ciprofloxacin encapsulated (Di Ninno et al., 1993). Even
with this very early formulation, results were very promising.
Efficacy was evaluated in a murine model of tularemia in which
mice were infected with F. tularensis live vaccine strain (LVS).
The F. tularensis LVS strain is relatively avirulent in humans
(and hence has been used historically as a live vaccine for
humans) yet causes a lethal infection in mice and therefore
is commonly used as a surrogate for more virulent strains.
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In mice challenged intravenously with 103 CFU of F. tularen-
sis LVS, a single intravenous dose of liposomal ciprofloxacin
(50mg/kg) provided a high level of protection if administered
within 48 h of the challenge. Conversely, a single intravenous
dose of unencapsulated ciprofloxacin (50mg/kg) offered no mea-
surable protection even when administered 24 h post-challenge
(Di Ninno et al., 1993).
To model pneumonic tularemia, mice were challenged with
100 CFU of F. tularensis LVS via intranasal instillation. A
single dose of intranasal liposomal ciprofloxacin (50mg/kg)
provided better protection than a single dose of intranasal
ciprofloxacin (50mg/kg) when therapy was initiated at 2 or 3
days post-challenge (Di Ninno et al., 1993; Wong et al., 1995)
(Figure 1 shows 3 day data). The improved efficacy of intranasal
liposomal ciprofloxacin compared to intranasal ciprofloxacin
may be explained by the quick elimination of unencapsulated
ciprofloxacin from the lung. Following intranasal instillation,
unencapsulated ciprofloxacin is almost completely eliminated
from the lungs within 2 h (Wong et al., 1995). Liposome encapsu-
lation increased the half-life of ciprofloxacin in the mouse model
from 1 to 10 h, and ciprofloxacin could still be detected in the lung
of mice 24 h after dosing (Wong et al., 1995).
An alternative liposomal ciprofloxacin formulation, which
encapsulated 90% of the ciprofloxacin, was developed using
egg phosphatidylcholine and cholesterol in a 1:1 ratio (Conley
et al., 1997). The pneumonic tularemia mouse model was used
to evaluate the efficacy of this formulation delivered by the
inhalational route. This delivery route is more representative,
FIGURE 1 | Therapeutic efficacy of a single dose of ciprofloxacin or
liposomal ciprofloxacin against murine inhalational F. tularensis LVS
and Schu S4 infection. Mice were challenged with F. tularensis LVS by the
intranasal route (approximately 1 × 102 CFU at DRDC or 6 × 104 CFU at
Dstl) or F. tularensis Schu S4 by the aerosol route (10 CFU retained dose).
Treatment was initiated at 72 h post-challenge for LVS infections and 24 h
post-challenge in the Schu S4 study. Treatment included 50mg/kg of oral
ciprofloxacin, 50mg/kg of intranasal ciprofloxacin, 50mg/kg liposomal
ciprofloxacin, or 1mg/kg lung dose of aerosolized liposomal ciprofloxacin.
Graph shows percentage survival at the end of the experiment. LVS
(DRDC) data is adapted from Di Ninno et al. (1993) (Intranasal ciprofloxacin
and liposomal ciprofloxacin) and Wong et al. (2003) (aerosolized liposomal
ciprofloxacin). Schu S4 and LVS (Dstl) data is adapted from Hamblin et al.
(2014).
when compared to intranasal instillation, of the expected
human pulmonary administration using a nebulizer or inhaler.
In the pneumonic tularemia mouse model, a single dose of
aerosolized ciprofloxacin (1mg/kg lung dose) provided little or
no protection whereas a single dose of aerosolized liposomal
ciprofloxacin (1mg/kg lung dose) offered 100% protection even
when administered as late as 72 h post-challenge (Wong et al.,
2003) (Figure 1 shows 72 h data). In addition, a single dose
of aerosolized liposomal ciprofloxacin still offered a high level
of protection (87%) when administered at 96 h post-challenge
(Wong et al., 2003).
The efficacy of liposomal ciprofloxacin administered at such
late time points after challenge is encouraging as late initiation of
therapy increases the risk of a negative treatment outcome (Celebi
et al., 2006). The use of liposomal ciprofloxacin may widen the
window of opportunity for initiating therapy, providing more
time for a F. tularensis deliberate release to be detected and for
those affected to be successfully treated.
LIPOSOMAL CIPROFLOXACIN FORMULATION
DEVELOPMENT AND HUMAN CLINICAL TRIALS
Liposomal ciprofloxacin has been further developed by Aradigm
Corporation to improve encapsulation efficacy and increase the
shelf life. More than 99% of the ciprofloxacin is encapsulated in
this improved formulation, which has an extended shelf life of 24
months at 5◦C (Cipolla et al., 2010). The human clinical devel-
opment is summarized in Table 1. Aradigm Corporation initially
conducted a Phase 1 study in healthy volunteers and Phase 2a
studies in cystic fibrosis (CF) and non-cystic fibrosis bronchiecta-
sis (BE) patients with the liposomal formulation CFI (Lipoquin®,
also known as ARD-3100). The Phase 1 trials in healthy vol-
unteers demonstrated the safety and tolerability of 300mg CFI
daily for 7 days (Bruinenberg et al., 2010). A Phase 2a study in
patients with CF also demonstrated the potential to considerably
increase lung ciprofloxacin concentrations by aerosol adminis-
tration of CFI compared to orally administered ciprofloxacin. At
steady state, a 500mg oral dose of ciprofloxacin results in peak
sputum concentrations of 1.86µg/g in patients with CF (LeBel
et al., 1986). In contrast, following administration of CFI the
mean sputum concentration at day 7 was 88.4µg/g (Bruinenberg
et al., 2010).
The Phase 1 study with CFI also demonstrated the low sys-
temic exposure of ciprofloxacin; following the 300mg CFI dose,
the average peak plasma concentration was only 0.1µg/ml and
an area under the curve (AUC) was 0.9 h·µg/ml (Bruinenberg
et al., 2010). These values are considerably less than those for oral
ciprofloxacin, where a 750mg dose results in a peak concentration
of 3.8µg/ml and an AUC of 16.8 h·µg/ml (Lettieri et al., 1992).
This reduction in systemic exposure may reduce ciprofloxacin
associated side effects. It is believed that side effects or fear of
side effects was responsible for 4% of US postal workers ceas-
ing their ciprofloxacin medication during the 2001 USA anthrax
attack (Brechner et al., 2001). Therefore, the use of inhaled CFI
rather than oral ciprofloxacin may improve compliance with a
prophylaxis regimen.
Prior to entry into Phase 2b studies, Aradigm Corporation
evaluated an additional formulation, dual release ciprofloxacin
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Table 1 | Clinical phase 1 and 2 trials evaluating once daily dosing with CFI or DRCFI for treatment of patients with chronic Pseudomonas
aeruginosa infection.
Purpose/indication Formulation Trial design and subjects Main results References
Safety/tolerability/
pharmacokinetics
CFI Phase 1, open-label, 20 healthy
subjects. Treatment: doses of 150,
300, or 450mga for 1 day; 300mga for
7 days
Incidence of any adverse events was
low; no serious or severe adverse
events. Only three potential drug-related
adverse-events, all mild, not dose-related
Bruinenberg et al., 2010
Safety/tolerability/
pharmacokinetics
CFI and
DRCFI
Phase 1/2a, open-label, nine healthy
and six BEb subjects. Treatment: dose
ranging for CFI and DRCFI
No clinically relevant reduction in FEVc1.
All adverse events were mild (except for
a urinary tract infection, not
treatment-related)
Serisier, 2012
Cystic fibrosis CFI Phase 2a, open-label, single-arm, 22
well-treated adults with CFd.
Treatment: 14 days with 300 mga
Significant reduction in P. aeruginosa in
sputum; 6.9% absolute increase in FEVc1
vs. baseline; exceptionally good
pulmonary safety and tolerability
compared to historical controls
Bruinenberg et al., 2010
Non-CF
bronchiectasis
CFI Phase 2a, open-label, single-arm, 36
BEb adult patients. Treatment: 28 days
of either 150 or 300mga
Significant reduction in P. aeruginosa in
sputum; no difference between the two
doses; no decline in lung function
Bruinenberg et al., 2010
Non-CF
bronchiectasis
CFI Phase 2b, randomized, double-blind,
placebo-controlled, 95 adult BEb
patients. Treatment: 28 days of either
100 or 150mga vs. matching placebos
(ORBIT-1)
Both doses significantly reduced P.
aeruginosa in sputum vs. placebo;
treatment well tolerated—no need for
pre-treatment or rescue with
bronchodilators
Serisier, 2012
Non-CF
bronchiectasis
DRCFI Phase 2b, randomized, double -blind,
placebo-controlled, 42 BEb adult
patients. Treatment: 150mga vs.
matching placebo for six cycles of 28
days on/28 days off (ORBIT-2)
Significant reduction in P. aeruginosa in
sputum; median time to first pulmonary
exacerbation more than doubled with
DRCFI vs. placebo; DRCFI has better
respiratory adverse effects profile than
placebo
Serisier et al., 2013
aExpressed in terms of ciprofloxacin hydrochloride dose loaded in the nebulizer, of which approximately 15–20% is delivered to the lung.
bBronchiectasis.
cForced expired volume in 1 s.
dCystic fibrosis.
for inhalation (DRCFI, Pulmaquin®, also known as ARD-3150) in
a second Phase 1 study, with the view that a mixed pharmacoki-
netic profile combining the benefits of slow release with a tran-
sient initial peak of ciprofloxacin could provide incremental ben-
efits for patients. This formulation was the result of mixing equal
volumes of CFI and a solution of free ciprofloxacin. The DRCFI
treatment was well tolerated in the Phase 1 study (Serisier, 2012).
Subsequently, both CFI and DRCFI have been investigated
in patients with non-cystic fibrosis BE against placebo into two
Phase 2b trials (ORBIT-1 and 2). In ORBIT-1, both doses of CFI
were well tolerated and significantly reduced P. aeruginosa in spu-
tum vs. placebo (Serisier, 2012). In ORBIT-2, DRCFI treatment
also significantly reduced P. aeruginosa in sputum (Serisier et al.,
2013). Notably, the median time to the first pulmonary exacerba-
tion was more than two times longer in the patients treated with
DRCFI vs. those treated with placebo. The DRCFI therapy was
also well tolerated with the respiratory adverse effects profile of
the patients treated with DRCFI being better than that for patients
treated with placebo (Serisier et al., 2013).
FURTHER EVALUATION OF LIPOSOMAL CIPROFLOXACIN
AGAINST F. TULARENSIS
Utilizing the advanced product, CFI (Lipoquin®), the efficacy
of liposomal ciprofloxacin against F. tularensis has been further
evaluated. As ciprofloxacin prophylaxis is generally given orally,
inhaled CFI was compared to oral ciprofloxacin. In mice chal-
lenged intranasally with approximately 6 × 104 CFU of F.
tularensis LVS, the efficacy of oral ciprofloxacin (50mg/kg) and
intranasally instilled CFI (50mg/kg) could not be distinguished
as a single dose of either formulation offered full protection
against a lethal challenge, even when therapy was delayed until
72 or 96 h post-challenge (Hamblin et al., 2014) (see Figure 1
for 72 h data). This clearly highlights the limitations of using
reduced virulence F. tularensis strains for evaluating the efficacy
of antibiotics against tularemia.
To discriminate between the two formulations, a mouse model
of infection with the more virulent F. tularensis Schu S4 was used.
In these studies, mice were challenged with F. tularensis Schu S4
via the aerosol route, with each mouse exposed to approximately
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10 CFU. A single dose of aerosolized CFI (1mg/kg lung dose)
provided full protection against a lethal aerosol challenge. In con-
trast, a single dose, or 3 or 5 days of twice daily oral ciprofloxacin
treatment (50mg/kg) did not preventmortality, with all mice suc-
cumbing to the infection (Figure 1 shows the single dose data).
However, the 3 or 5 days course of twice daily oral ciprofloxacin
treatment did increase the time to death of infected mice when
compared to PBS treatment (Hamblin et al., 2014). Ciprofloxacin,
administered by the oral route, does enter the lungs and maximal
concentrations are similar to those achieved after an aerosol dose
of CFI. However, the clearance rate of ciprofloxacin from the lung
is 4000-fold higher than aerosolized CFI. Therefore, the superior
efficacy of CFI, compared to ciprofloxacin, against aerosolized
F. tularensis may be due to the persistence of CFI in the lungs
(Hamblin et al., 2014).
Interestingly, aerosolized CFI was found to be more effective
than intranasally instilled CFI, as a single dose of intranasally
instilled CFI (50mg/kg) did not prevent mortality (>10% of the
mice survived) (see Figure 1). This may be due to different lung
distribution following the two routes of administration, since
aerosolized CFI is distributed more uniformly throughout the
lung. The high level of protection offered by CFI against a highly
virulent strain of F. tularensis is encouraging and suggests further
in-depth studies are warranted.
FUTURE WORK
Further evaluation of the efficacy of liposomal ciprofloxacin
using mouse and non-human primate models of tularemia could
support an application for licensure by the FDA under the ani-
mal rule. Such studies could determine the maximum window
of opportunity for initiating therapy and the shortest regimens
that are effective. Dose ranging studies could inform device
selection by determining if an effective dose can be adminis-
tered using a small portable hand-held inhaler or if a higher
dose requiring delivery by a nebulizer is needed. For exam-
ple, the AERx® inhaler developed by Aradigm Corporation can
deliver 50µl in each metered dose. In comparison, nebulizers
can deliver more drug (6ml of DRCFI in Aradigm Corporation’s
clinical trials) but are larger and require a power source. These
studies could also enable a comparison of the two liposomal
ciprofloxacin formulations, CFI and DRCFI, to determine which
is more effective and therefore more appropriate as a tularemia
therapy.
In addition, studies to date have not investigated the efficacy
of inhaled liposomal ciprofloxacin against systemic tularemia,
which can develop from the pneumonic form. Co-treatment of
liposomal ciprofloxacin with an orally or intravenously deliv-
ered antibiotic may warrant investigation as this therapy regimen
could enable successful treatment of pneumonic infections that
have spread systemically.
CONCLUSION
CFI is a promising therapy for pneumonic tularemia, having the
potential to shorten the current prophylactic regimen used in
the event of a deliberate release of F. tularensis. CFI also offers
potential for enhanced therapeutic outcomes for the treatment
of naturally occurring tularemia caused by highly virulent strains
of F. tularensis. Further study of liposomal ciprofloxacin is war-
ranted to fully determine the utility of this formulation as a
tularemia therapy.
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